Source: Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced two oral presentations and one poster presentation at HepDART 2017 being held on December 3 - 7, 2017 in Kona, Hawaii.
Oral Presentation: “Controlling HBsAg as a Key Component of a Combination Strategy to Affect an HBV Cure” by Michael J. Sofia, Chief Scientific Officer
Oral and Poster Presentation #8: “A Next Generation HBV Capsid Inhibitor, AB-506: In Vitro and In Vivo Antiviral Characterization” by Nagraj Mani, Senior Principal Scientist
These presentations will be available by visiting the Investor section of www.arbutusbio.com and selecting Events and Presentations.
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.
Executive Vice President and Chief Financial Officer
Manager, Investor Relations